The impact of sodium-glucose cotransporter-2 inhibitors on the incidence, therapy, and outcomes of fournier gangrene: insights from a systematic review of case reports.

What Researchers Did

This systematic review examined the clinical characteristics, therapy, and outcomes of Fournier Gangrene in patients using sodium-glucose cotransporter-2 inhibitors by analyzing English language case reports.

What They Found

Out of 78 identified studies, 14 case reports were included, revealing that patients' age ranged from 34 to 72 years and SGLT2i use varied from 6 months to 6 years.

All included studies reported discontinuation of SGLT2i, replacement with other anti-diabetic drugs, and improved patient outcomes after treatment, with seven studies reporting discharge within 9-51 days.

Canadian Relevance

This systematic review does not have a direct Canadian connection.

Study Limitations

The findings are limited by the nature of case reports, which may not be generalizable to the broader patient population, and the small number of included studies.